GlassScriptPhysician profile
Swapnil Vaidya
NPI 1457575615
$5,700.87
in general payments reported to CMS, 2019-2025
34 companies · $1,609 in 2025
The $1,609 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,487 · 2020: $519 · 2021: $378 · 2022: $165 · 2023: $385 · 2024: $1,158 · 2025: $1,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,151.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,472.39 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $746.88 | 2019-2025 | Dupixent |
| Genzyme Corporation | $669.06 | 2019-2025 | |
| Genentech USA, INC. | $367.45 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $339.23 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Pfizer INC. | $249.01 | 2019-2025 | |
| Grifols USA, LLC | $224.45 | 2019-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $201.29 | 2020-2025 | Hyqvia, Takhzyro |
| Pharming Healthcare, INC. | $162.39 | 2019-2025 | Ruconest |
| Ars Pharmaceuticals Operations, INC. | $157.34 | 2025 | Neffy |
| Amgen INC. | $151.78 | 2022-2025 | Tezspire |
| Shire North American Group INC | $141.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $130.81 | 2019-2025 | |
| Csl Behring | $102.44 | 2019-2025 | Hizentra |
| Kaleo, INC. | $96.28 | 2019-2024 | Auvi-Q |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $76.96 | 2023-2025 | Orladeyo |
| Alk-Abello, INC | $67.36 | 2019-2023 | Grastek, Odactra |
| Optinose US, INC. | $52.23 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $49.88 | 2025 | Voquezna |
| Phadia US INC. | $46.54 | 2021-2025 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.25 | 2019-2021 | |
| Organon LLC | $33.68 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $30.92 | 2025 | Nemluvio |
| Azurity Pharmaceuticals, INC. | $28.00 | 2025 | Alvesco |
| Incyte Corporation | $27.76 | 2025 | Opzelura |
| Lilly USA, LLC | $18.30 | 2025 | Ebglyss |
| Greer Laboratories, INC. | $15.34 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swapnil Vaidya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.